A general assessment of the safety of HMG CoA reductase inhibitors (statins). Curr Atheroscler Rep. 2002;4:34 41. 131. Armitage J. The safety of statins in clinical practice. Lancet. 2007;370:1781 1790. doi: 10.1016/S0140-6736(07)60716-8. 132. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/ NHLBI clinical advisory on the use and safety of statins. Circulation. 2002;106:1024 1028. 133. Hindler K, Shaw AD, Samuels J, Fulton S, Collard CD, Riedel B. Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology. 2006;105:1260 1272; quiz 1289. 134. Kulik A, Ruel M. Statins and coronary artery bypass graft surgery: pre- operative and postoperative efficacy and safety. Expert Opin Drug Saf. 2009;8:559 571. doi: 10.1517/14740330903188413. 135. Vecchione C, Brandes RP. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ Res. 2002;91:173 179. 136. Billings FT 4th, Pretorius M, Siew ED, Yu C, Brown NJ. Early post- operative statin therapy is associated with a lower incidence of acute kidney injury after cardiac surgery. J Cardiothorac Vasc Anesth. 2010;24:913 920. 137. Le Manach Y, Godet G, Coriat P, Martinon C, Bertrand M, Fl ron MH, Riou B. The impact of postoperative discontinuation or continu- ation of chronic statin therapy on cardiac outcome after major vas- cular surgery. Anesth Analg. 2007;104:1326 1333. doi: 10.1213/01. ane.0000263029.72643.10. 138. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, St hle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass graft- ing for severe coronary artery disease. N Engl J Med. 2009;360:961 972. doi: 10.1056/NEJMoa0804626. 139. Kulik A, Shrank WH, Levin R, Choudhry NK. 